TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Purchased by NewEdge Advisors LLC

NewEdge Advisors LLC increased its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 4,549.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,928 shares of the biopharmaceutical company's stock after purchasing an additional 6,779 shares during the period. NewEdge Advisors LLC's holdings in TG Therapeutics were worth $209,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Quadrant Capital Group LLC raised its holdings in TG Therapeutics by 137.1% during the 4th quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock valued at $51,000 after buying an additional 975 shares during the period. Blue Trust Inc. raised its stake in shares of TG Therapeutics by 24.5% during the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after acquiring an additional 371 shares in the last quarter. Smartleaf Asset Management LLC boosted its holdings in shares of TG Therapeutics by 512.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock valued at $60,000 after purchasing an additional 1,594 shares during the period. Jones Financial Companies Lllp grew its stake in TG Therapeutics by 460.7% in the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock worth $64,000 after purchasing an additional 1,737 shares in the last quarter. Finally, Synergy Asset Management LLC bought a new stake in TG Therapeutics during the 4th quarter valued at $75,000. Institutional investors own 58.58% of the company's stock.

TG Therapeutics Stock Down 4.3 %

Shares of NASDAQ:TGTX traded down $1.93 during trading on Friday, reaching $43.44. The stock had a trading volume of 4,165,093 shares, compared to its average volume of 2,983,451. The firm's 50-day simple moving average is $38.56 and its 200 day simple moving average is $33.31. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a one year low of $15.16 and a one year high of $46.48. The company has a market capitalization of $6.90 billion, a P/E ratio of -434.36 and a beta of 2.21.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.07. The company had revenue of $108.19 million during the quarter, compared to the consensus estimate of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. As a group, research analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. HC Wainwright restated a "buy" rating and set a $55.00 price target on shares of TG Therapeutics in a research note on Tuesday, March 4th. StockNews.com raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $40.80.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.